Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss is linked to a higher rate of body dysmorphic disorder (BDD), OCD, and depression. Finasteride and dutasteride are not linked to increased suicidal risk, though some users report mental health side effects.

Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.

A 26-year-old male has been using finasteride for 4.5 years to maintain hair and recently started taking dutasteride weekly due to increased hair shedding. He plans to gradually switch to dutasteride while monitoring side effects and hair changes.

A user is using a Finoxidil topical spray and is curious if oral Finasteride would be more effective, considering they are already on a DHT blocker called Cyproterone. They are concerned about the potential impact of oral Finasteride on their transition.

PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.

Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.

The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.

A 36-year-old started using finasteride (0.3-0.5mg daily), 5% minoxidil foam, and weekly dermarolling/dermapen treatments to address hair loss. They also began taking supplements for low ferritin and vitamin D, hoping to improve hair thickness and cover a bald spot.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

Finasteride can affect hormone levels within two weeks, and a break of several weeks is recommended for baseline results. Monitoring E2 and testosterone is suggested to assess the risk of gynecomastia.

Finasteride can affect hormone levels, potentially causing symptoms like puffy nipples and testicular pain, and may result in elevated prolactin and high testosterone. The user is seeking interpretation of these changes after taking finasteride.

A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.

User experienced hair thickening with pyri but also side effects like reduced sex drive. Stopping pyri and returning to CB restored sex drive, suggesting pyri may go systemic or be incorrectly formulated.

Finasteride users report reduced libido and increased hair shedding initially, but some see these as temporary or manageable side effects. Vitamin E and D-3 supplements are discussed as potential aids for libido and mood.

A dermatologist recommended PRP (Platelet Rich Plasma) and GFC (Growth Factor Concentrate) for pattern baldness, but online sources suggest they may not be effective. The user is seeking opinions on these treatments.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

A user's experience with hair loss treatments, including finasteride and other options such as RU58841, Nizoral, Pumpkin Seed, and Adenosine; the importance of being in a positive frame of mind when considering taking finasteride; and the need to address life issues before starting finasteride.

The user shared progress pictures after 4 months of using 1.25 mg oral Finasteride every other day. Responses indicate hair regrowth and a filling hairline, with one user asking about side effects or shedding.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

A user is excited to start using Pyriltamide for hair loss after experiencing side effects from topical finasteride. Other users discuss the potential and skepticism of Pyriltamide compared to older treatments like finasteride and RU58841.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

A 28-year-old male using only oral finasteride 1mg since May 15, 2024, reports no side effects and significant hair improvement. He plans to continue finasteride for three more months and is considering adding D3+K2 drops, zinc, folate, and magnesium glycinate.

The post discusses hair loss treatment progress using oral finasteride 1mg daily for 6 months, with improvements in the hairline but not the crown. The user avoids minoxidil due to side effects and plans to try PP405 for better density.

Hair loss treatments, specifically Pyrilutamide and Minoxidil/Finasteride/RU58841. Participants discussed their experiences with them and the results they have seen so far.

Finasteride use and its impact on male fertility. A user shared that they had no issues conceiving while using finasteride.

PP405 is expected to be a promising addition to hair loss treatments, potentially working well with existing treatments like finasteride and minoxidil, but not as a standalone solution. Users are hopeful for its effectiveness, especially in combination with other treatments, though expectations vary.

User switched from Fin to Dut for better hair loss results, using 0.5mg Dut and 1ml Min daily. Some discuss potential side effects and benefits of Dut compared to Fin.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

Finasteride and dutasteride, used for hair loss, can cause sexual dysfunction, depression, and suicidal thoughts, with some effects persisting after stopping. The post stresses the importance of being aware of these risks.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.